BioSpace News Archive

The Evolut TAVI Platform Receives New Indication for Patients with Bicuspid Aortic Valves at Extreme, High or Intermediate Risk of Surgical Mortality

--World-Class Monoclonal Antibody Technology Advances Beyond Infectious Disease to Focus on Oncology Therapeutics Derived from Cancer Survivors-- --Lead Asset AT1412 On Track Towards CTA Filing in Q4 2020-- --Led by New Management Team, Including John Womelsdorf, Ph.D., and Hans van Eenennaam, Ph.D., Co-inventor of Pembrolizumab-- l

The Company’s Presentation Slot is Confirmed for July 10, 2020 (Day 4) - Market Segment: CBD – BRANDED GOODS Out of Over 100 Applications, Alibaba Selected Tauriga Sciences, Inc. as a Top 10 Corporate Exhibitor NEW YORK, NY , June 22, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ‒ Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate,

Preliminary safety and efficacy data is being presented today from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients. Clinical responses and disease control—without serious side effects—in heavily pre-treated patients with metastatic breast cancer seen with lead candidate, Bria-IMT™, with or without a PD-1 inhibitor. Patients with “moderately” or “well” differentiated tumors showed a higher rate of dis

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced preclinical data presentation for TG-1701, the Company’s highly selective, BTK inhibitor, at the 2020 American Association for Cancer Research (AACR) annual meeting, being held virtually. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, “We are encouraged by the preclinical data presented today which showed TG-1701 to be just as active and more selective for

NuProbe and Weigao Group announced a strategic collaboration, wherein the two parties will apply NuProbe’s proprietary Blocker Displacement Amplification (BDA) technology to developing a liquid biopsy NGS panel for non-small cell lung cancer (NSCLC). The product will be compatible with the desktop NGS instruments, and the companies plan to l

The Lung Cancer Research Foundation (LCRF) today announced that Dr. Trudy Oliver has joined its Scientific Advisory Board.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the company will receive a $10 million milestone payment from Janssen Biotech, Inc. (Janssen) triggered under the Collaboration and License Agreement between the two companies. The milestone payment is associated with the first commercial sale in the European Union of Janssen’s

Medunik USA sponsors video series to support parents caring for their child’s sickle cell disease, which is causing morbidity and mortality to the African American community.

First Virtual Panel Features Renal Health Care Professionals Sharing Best Practices for Chronic Kidney Disease Patient Care in the COVID-19 Environment